Can text reminders help black and latinx women stay HIV-Free?

NCT ID NCT05165745

Recruiting now Prevention Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how to help cisgender women and transgender individuals, especially Black and Latinx communities, start and stick with PrEP—a daily pill that prevents HIV. Researchers will give personalized feedback to participants based on their adherence. The goal is to understand preferences and improve retention in care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pre-exposure prophylaxis (PrEP) medication
What this could lead to: If successful, this could improve how clinics support women and trans individuals in staying on HIV prevention medication, reducing new infections.
What could go wrong: This is a small, early-stage behavioral study (175 participants) focused on feedback and preferences, not testing a new drug. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION PRE EXPOSURE PROPHYLAXIS

Contacts and locations

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.